ANRO Alto Neuroscience
- 11.930
- +0.410+3.56%
Alto Neuroscience News
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D.,
Alto Neuroscience Appoints Michael Hanley As Chief Operating Officer >ANRO
Alto Neuroscience Appoints Michael Hanley As Chief Operating Officer >ANRO
Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment
TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience | 10-Q: Quarterly report
Alto Neuroscience Q1 2024 Adj EPS $(0.76) Misses $(0.46) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.46) by 65.22 percent.
Alto Neuroscience Sees Cash Position to Support Planned Ops Into 2027 >ANRO
Alto Neuroscience Sees Cash Position to Support Planned Ops Into 2027 >ANRO
Alto Neuroscience 1Q Loss/Shr 76c >ANRO
Alto Neuroscience 1Q Loss/Shr 76c >ANRO
Press Release: Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia -- -- Reported positive Phase
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
– Breadth of Alto's pipeline and Precision Psychiatry Platform will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Recently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with
Alto Neuroscience Schizophrenia Treatment Shows Good Phase 1 Results
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated with PDE4
Alto Neuroscience Has Initiated Phase 2 Study Of ALTO-203 In Major Depressive Disorder; Alto Expects To Report Topline Data From This Study In 1H Of 2025
Alto Neuroscience Has Initiated Phase 2 Study Of ALTO-203 In Major Depressive Disorder; Alto Expects To Report Topline Data From This Study In 1H Of 2025
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients With Major Depressive Disorder
Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 demonstrated a
Alto Neuroscience(ANRO.US) Officer Buys US$100.63K in Common Stock
$Alto Neuroscience(ANRO.US)$ Officer Smith Nicholas Conrad purchased 6,150 shares of Common Stock on Mar 28, 2024 at an average price of $16.36 for a total value of $100.63K.Source: Announcement What
Stifel Reiterates Buy on Alto Neuroscience, Maintains $32 Price Target
Stifel analyst Paul Matteis reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $32 price target.
Stifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
Buy Rating Affirmed for Alto Neuroscience on Strong Pipeline and Solid Financials
Buy Rating Affirmed: Alto Neuroscience's Promising Clinical Trials Signal Market Potential
Analysis
Price Target
No Data
